Assessment of Neuroendocrine Changes and Hypothalamo-Pituitary Autoimmunity in Patients with COVID-19

Abstract

SARS-CoV-2 may affect the hypothalamic-pituitary axis and pituitary dysfunction may occur. Therefore, we investigated neuroendocrine changes, in particular, secondary adrenal insufficiency, using a dynamic test and the role of autoimmunity in pituitary dysfunction in patients with COVID-19. The single-center, prospective, case-control study included patients with polymerase chain reaction (PCR)-confirmed COVID-19 and healthy controls. Basal hormone levels were measured, and the adrenocorticotropic hormone (ACTH) stimulation test was performed. Antipituitary (APA) and antihypothalamic antibodies (AHA) were also determined. We examined a total of 49 patients with COVID-19 and 28 healthy controls. The frequency of adrenal insufficiency in patients with COVID-19 was found as 8.2%. Patients with COVID-19 had lower free T₃, IGF-1, and total testosterone levels, and higher cortisol and prolactin levels when compared with controls. We also demonstrated the presence of APA in three and AHA in one of four patients with adrenal insufficiency. In conclusion, COVID-19 may result in adrenal insufficiency, thus routine screening of adrenal functions in these patients is needed. Endocrine disturbances in COVID-19 are similar to those seen in acute stressful conditions or infections. Pituitary or hypothalamic autoimmunity may play a role in neuroendocrine abnormalities in COVID-19.

Key words

COVID-19 - hypothalamic-pituitary axis - antihypothalamic antibodies - antipituitary antibodies - ACTH stimulation test - adrenal insufficiency

Publikationsverlauf

Eingereicht: 21. November 2021

Angenommen nach Revision: 27. Januar 2022

Artikel online veröffentlicht:
11. März 2022

• References

• 1 Johns Hopkins University. “COVID-19 dashboard by the center for systems science and engineering (CSSE) at Johns Hopkins University (JHU).” Im Internet: https://gisanddata.maps.arcgis.com/apps/dashboards/bda7594740fd40299423467b48e9ecf6Stand: 11/09/2021
• 2 Baj J, Karakuła-Juchnowicz H, Teresiński G. et al. COVID-19: Specific and non-specific clinical manifestations and symptoms: The current state of knowledge. J Clin Med 2020; 9: 1-22
• 3 Roberts CM, Levi M, McKee M. et al. COVID-19: a complex multisystem disorder. Br J Anaesth 2020; 125: 238-242
• 4 Wang W, Xu Y, Gao R. et al. Detection of SARS-CoV-2 in different types of clinical specimens. JAMA 2020; 323: 1843-1844
• 5 Yuki K, Fujiogi M, Koutsogiannaki S. COVID-19 pathophysiology: A review. Clin Immunol 2020; 215: 108427
• 6 Huang C, Wang Y, Li X. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395: 497-506
• 7 Li B, Yang J, Zhao F. et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol 2020; 109: 531-538
• 8 Chang L, Yan Y, Wang L. Coronavirus disease 2019: coronaviruses and blood safety. Transfus Med Rev 2020; 34: 75-80
• 9 Liu F, Long X, Zhang B. et al. ACE2 expression in pancreas may cause pancreatic damage after SARS-CoV-2 infection. Clin Gastroenterol Hepatol 2020; 18: 2128-2130.e2
• 10 Marazuela M, Giustina A, Puig-Domingo M. Endocrine and metabolic aspects of the COVID-19 pandemic. Rev Endocr Metab Disord 2020; 21: 495-507
• 11 Lundholm MD, Poku C, Emanuele N. et al. SARS-CoV-2 (COVID-19) and the Endocrine System. J Endocr Soc 2020; 4: 1-13
• 12 Somasundaram NP, Ranathunga I, Ratnasamy V. et al. The impact of SARS-Cov-2 virus infection on the endocrine system. J Endocr Soc 2020; 4: bvaa082
• 13 Mongioì LM, Barbagallo F, Condorelli RA. et al. Possible long-term endocrine-metabolic complications in COVID-19: lesson from the SARS model. Endocrine 2020; 68: 467-470
• 14 Pal R, Banerjee M. COVID-19 and the endocrine system: exploring the unexplored. J Endocrinol Invest 2020; 43: 1027-1031
• 15 Rhee E-J, Kim JH, Moon SJ. et al. Encountering COVID-19 as endocrinologists. Endocrinol Metab 2020; 35: 197-205
• 16 Puig-Domingo M, Marazuela M, Giustina A. COVID-19 and endocrine diseases. A statement from the European Society of Endocrinology. Endocrine 2020; 68: 2-5
• 17 Chiloiro S, Capoluongo ED, Tartaglione T. et al. The changing clinical spectrum of hypophysitis. Trends Endocrinol Metab 2019; 30: 590-602
• 18 Tanriverdi F, De Bellis A, Teksahin H. et al. Prospective investigation of pituitary functions in patients with acute infectious meningitis: Is acute meningitis induced pituitary dysfunction associated with autoimmunity?. Pituitary 2012; 15: 579-588
• 19 Alzahrani AS, Mukhtar N, Aljomaiah A. et al. The impact of COVID-19 viral infection on the hypothalamic-pituitary-adrenal axis. Endocr Pract 2021; 27: 83-89
• 20 Hashim M, Athar S, Gaba WH. New onset adrenal insufficiency in a patient with COVID-19. BMJ Case Rep 2021; 14: e237690
• 21 Heidarpour M, Vakhshoori M, Abbasi S. et al. Adrenal insufficiency in coronavirus disease 2019: a case report. J Med Case Rep 2020; 14: 134
• 22 Tan T, Khoo B, Mills EG. et al. Association between high serum total cortisol concentrations and mortality from COVID-19. Lancet Diabetes Endocrinol 2020; 8: 659-660
• 23 Mao Y, Xu B, Guan W. et al. The adrenal cortex, an underestimated site of SARS-CoV-2 infection. Front Endocrinol (Lausanne) 2021; 11: 593179
• 24 National Health Commission of the People’s Republic of China. Full-text: diagnosis and treatment protocol for COVID-19 patients (Tentative 8th Edition). In Internet: http://regional.chinadaily.com.cn/pdf/DiagnosisandTreatmentProtocolforCOVID-19Patients(Tentative8thEdition).pdfStand: 01/17/2021
• 25 Bidlingmaier M, Friedrich N, Emeny RT. et al. Reference intervals for insulin-like growth factor-1 (IGF-I) from birth to senescence: results from a multicenter study using a new automated chemiluminescence IGF-I immunoassay conforming to recent international recommendations. J Clin Endocrinol Metab 2014; 99: 1712-1721
• 26 Fliers E, Bianco AC, Langouche L. et al. Thyroid function in critically ill patients. Lancet Diabetes Endocrinol 2015; 3: 816-825
• 27 Dickstein G. Low dose ACTH test: a word of caution to the word of caution: when and how to use it. J Clin Endocrinol Metab 1997; 82: 322-322
• 28 Patti G, Calandra E, De Bellis A. et al. Antibodies against hypothalamus and pituitary gland in childhood-onset brain tumors and pituitary dysfunction. Front Endocrinol (Lausanne) 2020; 11: 16
• 29 Bellastella G, Rotondi M, Pane E. et al. Predictive role of the immunostaining pattern of immunofluorescence and the titers of antipituitary antibodies at presentation for the occurrence of autoimmune hypopituitarism in patients with autoimmune polyendocrine syndromes over a five-year follow-up. J Clin Endocrinol Metab 2010; 95: 3750-3757
• 30 Michalaki M. Dissociation of the early decline in serum T3 concentration and serum IL-6 rise and TNF in nonthyroidal illness syndrome induced by abdominal surgery. J Clin Endocrinol Metab 2001; 86: 4198-4205
• 31 Croce L, Gangemi D, Ancona G. et al. The cytokine storm and thyroid hormone changes in COVID-19. J Endocrinol Invest 2021; 44: 891-904
• 32 Leow MK-S, Kwek DS-K, Ng AW-K. et al. Hypocortisolism in survivors of severe acute respiratory syndrome (SARS). Clin Endocrinol (Oxf) 2005; 63: 197-202
• 33 Wang W, Ye Y, Yao H. Evaluation and observation of serum thyroid hormone and parathyroid hormone in patients with severe acute respiratory syndrome. J Chin Antituberculous Assoc 2003; 25: 232-234
• 34 Chen M, Zhou W, Xu W. Thyroid function analysis in 50 patients with COVID-19: a retrospective study. Thyroid 2021; 31: 8-11
• 35 Chen T, Wu D, Chen H. et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ 2020; m1091
• 36 Gao W, Guo W, Guo Y. et al. Thyroid hormone concentrations in severely or critically ill patients with COVID-19. J Endocrinol Invest 2021; 44: 1031-1040
• 37 Arnold J, Campbell IT, Samuels TA. et al. Increased whole body protein breakdown predominates over increased whole body protein synthesis in multiple organ failure. Clin Sci 1993; 84: 655-661
• 38 Baxter RC. Changes in the IGF–IGFBP axis in critical illness. Best Pract Res Clin Endocrinol Metab 2001; 15: 421-434
• 39 Langouche L, Van den Berghe G. Hypothalamic–pituitary hormones during critical illness. Handb Clin Neurol 2014; 124: 115-126
• 40 Lubrano C, Masi D, Risi R. et al. Is growth hormone insufficiency the missing link between obesity, male gender, age, and COVID-19 severity?. Obesity 2020; 28: 2038-2039
• 41 Gilliver SC. Sex steroids as inflammatory regulators. J Steroid Biochem Mol Biol 2010; 120: 105-115
• 42 Xu J, Qi L, Chi X. et al. Orchitis: A complication of severe acute respiratory syndrome (SARS)1. Biol Reprod 2006; 74: 410-416
• 43 Channappanavar R, Fett C, Mack M. et al. Sex-based differences in susceptibility to severe acute respiratory syndromecoronavirus infection. J Immunol 2017; 198: 4046-4053
• 44 Ma L, Xie W, Li D. et al. Evaluation of sex-related hormones and semen characteristics in reproductive-aged male COVID-19 patients. J Med Virol 2021; 93: 456-462
• 45 Vilar L, Abucham J, Albuquerque JL. et al. Controversial issues in the management of hyperprolactinemia and prolactinomas – an overview by the neuroendocrinology department of the Brazilian society of endocrinology and metabolism. Arch Endocrinol Metab 2018; 62: 236-263
• 46 Gu WT, Zhou F, Xie WQ. et al. A potential impact of SARS-CoV-2 on pituitary glands and pituitary neuroendocrine tumors. Endocrine 2021; 72: 340-348
• 47 Aygen B, Inan M, Doğanay M. et al. Adrenal functions in patients with sepsis. Exp Clin Endocrinol Diabetes 2009; 105: 182-186
• 48 Wheatland R. Molecular mimicry of ACTH in SARS – implications for corticosteroid treatment and prophylaxis. Med Hypotheses 2004; 63: 855-862
• 49 Pal R. COVID-19, hypothalamo-pituitary-adrenal axis and clinical implications. Endocrine 2020; 68: 251-252
• 50 Tanriverdi F, Karaca Z, Unluhizarci K. et al. The hypothalamo-pituitary-adrenal axis in chronic fatigue syndrome and fibromyalgia syndrome. Stress 2007; 10: 13-25
• 51 Karaca Z, Lale A, Tanriverdi F. et al. The comparison of low and standard dose ACTH and glucagon stimulation tests in the evaluation of hypothalamo-pituitary-adrenal axis in healthy adults. Pituitary 2011; 14: 134-140
• 52 Simsek Y, Karaca Z, Tanriverdi F. et al. A comparison of low-dose ACTH, glucagon stimulation and insulin tolerance test in patients with pituitary disorders. Clin Endocrinol (Oxf) 2015; 82: 45-52
• 53 Karaca Z, Grossman A, Kelestimur F. Investigation of the hypothalamo-pituitary-adrenal (HPA) axis: a contemporary synthesis. Rev Endocr Metab Disord 2021; 22: 179-204
• 54 Dökmetaş HS, Çolak R, Keleştimur F. et al. A comparison between the 1-mg adrenocorticotropin (ACTH) test, the short ACTH (250 μg) test, and the insulin tolerance test in the assessment of hypothalamo-pituitary-adrenal axis immediately after pituitary surgery. J Clin Endocrinol Metab 2000; 85: 3713-3719
• 55 Clarke SA, Phylactou M, Patel B. et al. Normal adrenal and thyroid function in patients who survive COVID-19 infection. J Clin Endocrinol Metab 2021; 106: 2208-2220